Searched for
TIRZEPATIDE MARKET PERFORMANCE
Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?The rise of GLP-1 weight-loss drugs such as Ozempic is posing a challenge to the fitness industry, with cheaper generic versions expected t...
- Table 2.0: Restaurants absorb 'Ozempic effect' for weight-loss drug consumersIndian restaurants are adapting to a growing consumer base using weight-loss medications like Ozempic and Mounjaro by introducing "Size O" ...
- NVO stock crashes 14%: Why Novo Nordisk shares are down today? 2026 sales forecast and Eli Lilly competition explainedNVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...
- 'Chinese peptides' are the latest biohacking trend in the tech worldTech professionals are embracing unapproved Chinese peptides for weight loss, fitness, and productivity. These substances, often sourced di...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli LillyEli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...
- Weight loss drugs can wreak havoc on your face, warn expertsA drug overdose is bad news for your beauty.
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...
Load More
